Literature DB >> 1510705

Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs.

K N Bangchang1, J Karbwang, D J Back.   

Abstract

A number of drugs have been studied for their effect on the metabolism of the antimalarial drug primaquine by human liver microsomes (N = 4) in vitro. The only metabolite generated was identified as carboxyprimaquine by co-chromatography with the authentic standard. Ketoconazole, a known inhibitor of cytochrome P450 isozymes, caused marked inhibition of carboxyprimaquine formation with IC50 and K(i) values of 15 and 6.7 microM, respectively. This finding and the dependency of metabolite formation on NADPH indicates that cytochrome P450 isozyme(s) catalysed metabolite production. Of compounds actually or likely to be coadministered with primaquine to malaria patients, only mefloquine produced any inhibition (K(i) = 52.5 microM). Quinine, artemether, artesunate, halofantrine and chloroquine did not significantly inhibit metabolite formation. It seems unlikely that the concurrent administration of mefloquine, or other antimalarials, with primaquine will lead to appreciably altered disposition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510705     DOI: 10.1016/0006-2952(92)90453-p

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?

Authors:  Bui Tri Cuong; Vu Quoc Binh; Bui Dai; Dinh Ngoc Duy; Claire M Lovell; Karl H Rieckmann; Michael D Edstein
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Authors:  Rita Piedade; Stefanie Traub; Andreas Bitter; Andreas K Nüssler; José P Gil; Matthias Schwab; Oliver Burk
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

4.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

5.  Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Authors:  K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

Review 6.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 7.  Pharmacokinetics of artemisinin-type compounds.

Authors:  V Navaratnam; S M Mansor; N W Sit; J Grace; Q Li; P Olliaro
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 8.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

9.  Interactions among primaquine, malaria infection and other antimalarials in Thai subjects.

Authors:  G Edwards; C S McGrath; S A Ward; W Supanaranond; S Pukrittayakamee; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 10.  Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria.

Authors:  L B Barradell; A Fitton
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.